EpiPen

Pharmalot By Ed Silverman

Most Americans believe prescription drug prices are unreasonable

Pharmalot By Ed Silverman

Lawmakers ask Justice Department to probe Mylan over Medicaid rebates

First Opinion By James R. Baker Jr.

EpiPen pricing controversy reflects larger issues in pharma industry

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Most Californians support proposed law to limit drug prices

The Pharmalot View By Ed Silverman

Behind the grandstanding, Congress may have taken a key step to clarifying drug prices

Business By Ike Swetlitz

Lawmakers lash out at Mylan over EpiPen profit revision

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Mylan’s parent bloggers feel jilted thanks to price hikes

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Congress probes FDA’s Office of Criminal Investigations

Business By Ike Swetlitz

Anger at EpiPen prices channeled at Mylan CEO in congressional hearing

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Mylan CEO’s mom helped push EpiPen to schools

Business By Ike Swetlitz

Mylan CEO says company failed to properly heed concern over EpiPen prices

Business By Ike Swetlitz

4 questions we’d like answered in Heather Bresch’s congressional appearance

Pharmalot By Ed Silverman

California governor decries ‘predatory’ pricing as he signs law to make EpiPen available

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Mylan quietly pushes effort to blunt impact of EpiPen pricing

Pharmalot By Ed Silverman

Lawmakers ask HHS to probe the Medicaid drug rebate program

Pharmalot By Ed Silverman

Bipartisan bill in Congress would require drug makers to justify, limit price hikes

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Mylan CEO to testify about EpiPen before Congress next week

Video By Ike Swetlitz

Watch: How EpiPens — and epinephrine — stop a serious allergic reaction

Business By Associated Press

The pros and cons of drug coupon cards

Pharmalot By Ed Silverman

Pharma suffers a setback in battle over Ohio drug pricing ballot measure

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Teva expects FDA to speed review of its generic EpiPen

Business By Meghana Keshavan

5 reasons why no one has built a better EpiPen

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Are concerns about spending on orphan drugs overblown?

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Immunotherapy is complicating clinical trial designs

Pharmalot By Ed Silverman

Q&A: Allergan’s CEO speaks out on limiting drug prices. ‘Somebody had to take the first step’

Business By Ike Swetlitz

Mylan faces two potential class action lawsuits over EpiPen pricing

Business By Ike Swetlitz

EpiPen maker under investigation for antitrust violations in New York

Pharmalot By Ed Silverman

Allergan CEO promises to limit price hikes on drugs in a bid to rebuild the ‘social contract’

Pharmalot By Ed Silverman

Anyone see the rebates? Lawmakers accuse Mylan of underpaying Medicaid for EpiPen